​​​​© 2018 pMedGR Project Management

SCOPE

 

pMedGR aims at supporting research and innovation towards next generation healthcare applications. Specifically, the infrastructure aims at re-designing ongoing and prospective clinical trials, linking them with molecular profiles obtained through high-throughput ‘omics’ technologies towards more efficient and cost-effective health and disease management for European citizens.

 

pMedGR offers a unique opportunity for obtaining real added value for the European and regional social market economy and has a high potential for attracting private investments, maximizing synergies between national and EU funding schemes and thus mobilizing, leveraging and bundling different types of public and private funding. It combines economic viability with high-socioeconomic returns in the area of healthcare management and brings together the industrial sector, clinicians, medical researchers, biomedical scientists and technology experts, thus providing the necessary means to initiate and develop innovation.

News & Events

16-01-2018

The pMed Kick-off meeting took place on December 12th, 2017 at the University of Athens.

08-09-2017

pMedGR (MIS 5002802) ranked in the Top10 Infrastructures to receive funding under the call 039  "STRENGTHENING RESEARCH AND INNOVATION INFRASTRUCTURE".

14-10-2015

pMedGR is one of the eight Biomedical Research Infrastructures included in the new National Roadmap that has just been launched.

The Greek Research Infrastructure for Personalised Μedicine

 

Towards more accurate and cost-effective health management for the Greek citizen

Center of New Biotechnologies & Precision Medicine

 
Enabling precision prognosis, diagnosis & therapy of diseases through advances in Biotechnology
Our Goals

  • Strengthen basic research

  • Harness the “big data” revolution

  • Revise clinical trial designs

  • Move regulatory science forward

  • Foster collaboration

  • Enhance patient access to innovative medicines

  • Revise clinical trial designs

A specialized regional 
“meta-structure”

 

  • Pharmaceutical R&D departments 

  • Biotechnology SMEs and diagnostics developers

  • Biomedical and clinical researchers

  • National and European biomedical research infrastructures

  • Patients and patient foundations

  • Policy-makers